This is not the most recent version of the article. View current version (3 AUG 2014)

Intervention Protocol

Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia

  1. Magdolna Tardy1,*,
  2. Stefan Leucht1,
  3. Andrey Potapov2,
  4. Rolf Engel3,
  5. Maximilian Huhn1,
  6. Werner Kissling1

Editorial Group: Cochrane Schizophrenia Group

Published Online: 10 AUG 2011

DOI: 10.1002/14651858.CD009230


How to Cite

Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD009230. DOI: 10.1002/14651858.CD009230.

Author Information

  1. 1

    Technische Universität München Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Germany

  2. 2

    Moscow Scientific Research Institute of Psychiatry, Moscow, Russian Federation, Russian Federation

  3. 3

    Klinikum der Ludwig-Maximilians Universitat, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Munchen, Germany

*Magdolna Tardy, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Möhlstr. 26, München, 81675, Germany. Magdolna.Tardy@lrz.tu-muenchen.de.

Publication History

  1. Publication Status: New
  2. Published Online: 10 AUG 2011

SEARCH

This is not the most recent version of the article. View current version (03 AUG 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Tor evaluate the effects of the high-potency antipsychotic drug fluphenazine versus low-potency antipsychotic drugs. Fluphenazine is clinically perceived to be more efficacious than other low-potency drugs, and in this review we will test the hypothesis that fluphenazine is more effective than other low-potency antipsychotic drugs.